Objective: Epidemiological studies suggest vitamin D deficiency as a potential risk factor for rheumatoid arthritis (RA) development, a chronic autoimmune disorder highly prevalent in indigenous North American (INA) population. We therefore profiled the circulating levels of 25-hydroxyvitaminD [25(OH)D], an active metabolite of vitamin D, in a cohort of at-risk first-degree relatives (FDR) of INA RA patients, a subset of whom subsequently developed RA (progressors). Methods: 2007 onward, serum samples from INA RA patients and FDR were collected at the time of a structured baseline visit and stored at -20°C. Anti-citrullinated protein antibodies (ACPA), 25(OH)D, hs-CRP, vitamin-D binding protein (VDBP) levels were determined using ELISA and rheumatoid factor (RF) seropositivity was determined by nephelometry. Results: We demonstrate that 25 (OH) D concentrations were lower in winter than summer (P=0.0538), and that serum 25(OH)D levels were higher in samples collected and stored after 2013 (P<0.0001). Analysis of samples obtained after 2013 demonstrated that 37.6% of study participants were 25(OH)D insufficient (<75nmol/L). Also, seropositive RA patients and FDR had lower 25(OH)D levels compared to ACPA-/FDR (P<0.05, P<0.01 respectively). Linear regression analysis showed 25(OH)D insufficiency was inversely associated with presence of RA autoantibodies. Longitudinal samples from 14 progressors demonstrated a consistent increase in 25(OH)D levels at the time they exhibited clinically detectable joint inflammation, without any significant change in VDBP levels.
INTRODUCTION

RA is a systemic autoimmune inflammatory disorder that disproportionately affects indigenous
North American (INA) population (1) . The reasons for this are incompletely understood and appear to relate to complex gene-environment interactions that initiate a break in immune tolerance and then accelerate the development of systemic and articular inflammation in susceptible individuals (2, 3) . Studies of the preclinical phase of RA have demonstrated seropositivity for RA autoantibodies such as rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA), elevations in pro-inflammatory cytokines and the presence of aberrant epigenetic processes (2) (3) (4) .
A role for lifestyle habits and diet as risk factors for the development of RA has been proposed (5, 6) . To date, the best documented lifestyle risk factor for RA development is tobacco smoking as described in multiple populations worldwide (7) . Several dietary risk factors have also been studied in epidemiologic and cohort studies (8, 9) . Since vitamin D deficiency has been shown to be prevalent in patients with early and established RA and an association with disease activity has been demonstrated, its potential role as a risk factor for RA development has been hypothesized (8, 10) . Currently, there are limited studies that can define this association beyond any reasonable doubt. Existing literature suggests that lower vitamin D intake is associated with increased RA risk, while hypovitaminosis D affects disease activity score, bone-mass index, and regulatory Tcell proliferation in treatment-naïve RA patients (10) .
Biologically synthesized inside the epidermis due a UV photolysis, vitamin D is hydroxylated by a family of cytochrome P450 enzymes called 25-hydroxylases to form 25(OH)D, the most predominant circulating form of vitamin D metabolite. 25(OH)D is further hydroxylated in the kidney and other tissues to form 1,25(OH) 2 D, the most biologically active form of vitamin D involved in maintenance of bone density, calcium absorption, and immunomodulation, including regulation of the metabolic phenotype of innate and adaptive immune cells (11) . Vitamin D inhibits the differentiation of tissue-resident antigen-presenting cells (APCs) like dendritic cells (DCs) and macrophages from monocytes and prevents their maturation. Alternatively, it promotes the formation of tolerogenic DCs from bone marrow-derived DCs. Active vitamin D is also shown to affect the polarization and activation of CD4 + T lymphocytes, inhibit IL-17 production from Th17 cells. induced regulatory T-cells and inhibit the production of pro-inflammatory cytokines and chemokines. Additionally, 1,25(OH) 2 D also suppresses the differentiation of human B-cells and stimulates the production of immunomodulatory host-defense proteins such as LL-37 (8, 10, 12, 13) In the current study, we evaluated the circulating levels of 25(OH)D, the active metabolite of vitamin D, in a cohort of first-degree relatives (FDR) of INA RA patients, and attempted to relate these levels to the onset of clinically detectable RA in individuals who ultimately developed disease. Our results suggest that, as with RA patients, ACPA seropositive FDR exhibit low levels of circulating 25(OH)D as a group, compared to ACPA seronegative FDR. Surprisingly, individuals who developed RA demonstrated an increase in 25(OH)D at the time of disease onset.
METHODS
Study Design:
INA study participants were recruited from Cree, Ojibway, and Ojicree communities in Central Canada (14, 15) from the winter and one from the summer for each FDR was included in the analysis. A subset of FDR who were followed longitudinally into RA onset, hereby referred to as "progressors", had serum samples from several preclinical time points available for analysis, along with a sample from the study visit where they were first noted to have the onset of joint inflammation (referred as transition point). This was defined as the presence of one or more swollen joints deemed by the study rheumatologist (HEG) to represent active synovitis (16) . 
RESULTS
Characteristics of the study participants
The study population consisted of RA patients (N=56), ACPA+/FDR (N=24), ACPA-/FDR (N=54), and FDR who progressed to develop RA while being followed in the study (progressors; N=14). The demographic and clinical characteristics of the study cohort are shown in Table 1 .
Most of the study cohort in all groups were females and the mean age was 47.8 + 13.2years (mean + SD), although the mean age of the progressors was younger than the rest of the cohort. Not unexpectedly, RA patients, as a group, had higher CRP levels than the FDR groups. All of the RA patients were on disease-modifying anti-rheumatic drugs (DMARD) and the mean DAS28 score was 3.4 + 1.2. The 14 progressors had a median age of 32 (23-68) years at the time they developed inflammatory arthritis. Table 1 : Clinical characteristics of the study participants -All values are reported as median (range). RA = Rheumatoid Arthritis, RF = rheumatoid factor, anti-CCP = anti cyclic citrullinated protein antibody, CRP = C-reactive protein, NA = not applicable, BMI = body mass index. 
ACPA-/FDR
Effect of storage time and seasonal variation on circulating levels of 25(OH)D
As shown in Table 2a , mean serum concentrations of 25(OH)D were significantly higher in samples collected and stored after 2013 (storage period < 5yrs) compared to samples collected before 2013 (storage period > 5yrs). Based on this, we corrected for the duration of storage by excluding samples collected and stored before 2013. (table 3) . As the bioavailability and biological activity of 25(OH)D is dependent on the circulating levels of VDBP with 85% of 25(OH)D being bound to VDBP(18), we tested VDBP levels in the same samples to determine whether the levels of this glycoprotein followed a similar pattern to the free 25(OH)D that were measured. This analysis showed that VDBP levels remained stable over time Circulating 25(OH)D concentrations in RA patients are known to be associated with the presence of ACPA and RF (25, 26) . However, current evidence is conflicting on the role of 25(OH)D and vitamin D during the preclinical stages of RA (27, 28) . In our INA cohort, we show that 25(OH)D concentrations in seropositive FDR, as with RA patients, are lower than in seronegative FDR.
Longitudinal analysis of 25(OH)D levels in progressors demonstrates that there is a consistent increase in levels at the onset of inflammatory arthritis compared with earlier time points.
In attempting to explain this unexpected finding, several possibilities can be considered. One important consideration is the potential confounding effects of duration of sample storage and seasonal variation on 25(OH)D levels. It is conceivable that 25(OH)D levels "appeared" to increase because of a decay in this analyte in older stored samples from the same individuals. We clearly demonstrate this duration of storage effect in samples stored > 5 years, with older samples having lower levels. Our data contrasts that of previous publications suggesting that duration of sample storage had minimal impact on 25(OH)D stability (29, 30) , although this decay may be less likely to occur if samples are stored at -80°C. Our analysis of the subgroup of 8 progressors whose samples were all gathered within the most recent five-year timeframe all showed increasing 25(OH)D levels at the time of IA onset. Moreover, this increase in levels was not observed in the longitudinal samples of seronegative individuals who did not develop IA. Together, these observations suggest that this phenomenon cannot be explained on the basis of time in storage of the samples.
We also demonstrate that samples gathered during the winter months, on average, exhibit lower levels of 25(OH)D compared to samples gathered in the summer months, results that are consistent with published literature in other populations, including in other INA communities (31, 32) . Of note, we show that a majority of our study participants had summer concentrations of 25(OH)D that were greater than 75nmol/L, with only 34% demonstrating levels deemed to be in the vitamin D insufficiency range. These results are consistent with studies in other INA communities (33) .
Nevertheless, our analysis suggests that seasonal variation does not account for the observed rise at the time of IA onset. Factors like increased exposure to sunlight or dietary intake of vitamin D supplements are insufficient as 25(OH)D levels remained consistently increased over a long period of time extending up to ~19months preceding onset of clinically detectable symptoms.
Previously, we showed that single-nucleotide polymorphism Fok1 (rs2228570) within the VDR gene is significantly associated with RA onset in INA population (34) . Additionally, systemic inflammation, obesity, and parathyroid hormone levels have been associated with changes in circulating vitamin D levels. (12, (35) (36) (37) (38) (39) (40) . 
